Format

Send to:

Choose Destination
See comment in PubMed Commons below
Dement Geriatr Cogn Disord. 2004;17(3):158-63. Epub 2004 Jan 20.

Results of quinacrine administration to patients with Creutzfeldt-Jakob disease.

Author information

  • 1Department of Neurology, Fukuoka University, Fukuoka, Japan. masashi@tokyoh.rofuku.go.jp

Abstract

Several chemicals inhibit the accumulation of abnormal prion proteins in vitro. We administered one, the antimalarial agent quinacrine, to three patients with sporadic Creutzfeldt-Jakob disease (CJD) and to one with iatrogenic CJD. Quinacrine at 300 mg/day was given enterally for 3 months. Within 2 weeks of administration, the arousal level of the patient with akinetic mutism improved. The other 3 patients, insensible before treatment, had integrative responses such as eye contact or voluntary movement in response to verbal and/or visual stimuli restored. Clinical improvement was transient, lasting 1-2 months during treatment. Quinacrine was well tolerated, except for liver dysfunction and yellowish pigmentation. Although its antiprion activity in the human brain has yet to be proved, these modest effects of quinacrine suggest the possibility of using chemical intervention against prion diseases.

Copyright 2004 S. Karger AG, Basel

PMID:
14739538
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Write to the Help Desk